Efficacy of salvage therapy of Helicobacter pylori-positive gastric mucosa-associated lymphoid tissue lymphoma

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Lymphomas
Cancer Treatment in Patients with Comorbidities
Presenter Sung-Nam Lim
Citation Annals of Oncology (2018) 29 (suppl_9): ix87-ix93. 10.1093/annonc/mdy437
Authors S. Lim1, S. Ko2, B.S. Sohn3, S.Y. Oh4
  • 1Internal Medicine, Inje University Haeundae Paik Hospital, 612-030 - Busan/KR
  • 2Internal Medicine, Haeundae Paik Hospital, 48108 - Busan/KR
  • 32department Of Internal Medicine, Inje University Sanggye Paik Hospital, 01757 - Seoul/KR
  • 4Hematology-oncology, Dong-A university College of Medicine, Busan/KR



Helicobacter pylori infection has a critical role in the pathogenesis of gastric mucosa-associated lymphoid tissue (MALT) lymphoma. However, in patients who do not achieve a lymphoma regression or relapse following antibiotic therapy, a long-term outcome of the patients are scarce. We evaluated the long-term outcome of the patients who received irradiation or chemotherapies with relapsed or refractory gastric MALT lymphoma.


Between June 2000 and June 2017, a total of 29 H.pylori-positive gastric MALT lymphoma patients who received frontline H.pylori eradication regimen were included in this study. H.pylori-positive status was defined by positive results for the biopsy urease test and histology. They had all been diagnosed by endoscopy and had a complete staging including CT-scan and bone marrow biopsies. Patients received standard triple therapy for eradication of H.pylori and after treatment were sequentially followed-up with endoscopies performed to evaluate the response. Tumors that had resolved to complete remission (CR) score of GELA histologic grading system were considered treatment-responsive.


During the follow-up periods 16 patients were refractory gastric MALT lymphoma, nine had probable minimal residual disease and four relapsed after the first-line antibiotics. Of these 29 patients, transformation into high-grade B-cell lymphoma did not occur. Among the non-responder and relapsed patients, three patients were subjected to a watch and wait, while 26 patients underwent second-line treatment including radiotherapy (n = 20), chemotherapy (n = 5), chemotherapy plus sequential radiotherapy (n = 1). Of the 20 patients treated with radiotherapy, the median dose to stomach was 3060 cGy. After radiotherapy a CR was achieved in 20 patients (100%). Among six patients who received chemotherapy, a CR was achieved in five patients and no change was in one. That patient was achieved CR after radiotherapy. Probabilities of freedom from treatment failure and overall survival after 10 years were 100% and 83%.


Outcome of patients with first-line H.pylori eradication failure followed by delayed chemotherapy and/or radiotherapy on indication was excellent.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Sung-Nam Lim.


Has not received any funding.


All authors have declared no conflicts of interest.